Crescent Biopharma (CBIO) Prepaid Assets (2013 - 2026)
Crescent Biopharma (CBIO) reported Prepaid Assets of $6.4 million for Q1 2026, up 2038.81% year-over-year from $299232.0 in Q1 2025, and up 17.15% on a QoQ basis from $5.5 million in Q4 2025.
Crescent Biopharma (CBIO) has 14 years of Prepaid Assets data on file, last reported at $6.4 million in Q1 2026.
- Quarterly Prepaid Assets rose 2038.81% year-over-year to $6.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.4 million (up 2038.81% YoY) and the FY2025 annual result came in at $5.5 million, up 14276.32% from the prior year.
- Prepaid Assets improved to $6.4 million in Q1 2026 per CBIO's latest filing, from $5.5 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $6.4 million in Q1 2026 and bottomed at $38000.0 in Q4 2024.
- The 5-year median for Prepaid Assets is $1.3 million (2025), against an average of $1.7 million.
- The widest annual swing landed in 2024, when Prepaid Assets plunged 98.1%; it then surged 14276.32% in 2025.
- Tracing CBIO's Prepaid Assets over 5 years: stood at $399861.0 in 2022, then surged by 399.65% to $2.0 million in 2023, then sank by 98.1% to $38000.0 in 2024, then surged by 14276.32% to $5.5 million in 2025, then grew by 17.15% to $6.4 million in 2026.
- Per Business Quant, the three latest CBIO Prepaid Assets figures stand at $6.4 million (Q1 2026), $5.5 million (Q4 2025), and $1.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Crescent Biopharma | 569.36 Mn | 380.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.40 Mn |
| Dec 31, 2025 | 5.46 Mn |
| Sep 30, 2025 | 1.30 Mn |
| Jun 30, 2025 | 1.58 Mn |
| Mar 31, 2025 | 299,232.00 |
| Dec 31, 2024 | 38,000.00 |
| Sep 30, 2024 | 798,274.00 |
| Jun 30, 2024 | 589,133.00 |
| Mar 31, 2024 | 859,909.00 |
| Dec 31, 2023 | 2.00 Mn |
| Sep 30, 2023 | 1.81 Mn |
| Jun 30, 2023 | 1.36 Mn |
| Mar 31, 2023 | 2.29 Mn |
| Dec 31, 2022 | 399,861.00 |
| Sep 30, 2022 | 2.22 Mn |
| Jun 30, 2022 | 1.02 Mn |
| Mar 31, 2022 | 459,866.00 |
| Dec 31, 2021 | 273,396.00 |
| Sep 30, 2021 | 2.21 Mn |
| Jun 30, 2021 | 520,298.00 |
| Mar 31, 2021 | 380,485.00 |
| Dec 31, 2020 | 965,504.00 |
| Sep 30, 2020 | 2.46 Mn |
| Jun 30, 2020 | 3.51 Mn |
| Mar 31, 2020 | 332,273.00 |
| Dec 31, 2019 | 4.33 Mn |
| Sep 30, 2019 | 3.91 Mn |
| Jun 30, 2019 | 2.30 Mn |
| Mar 31, 2019 | 2.83 Mn |
| Dec 31, 2018 | 1.61 Mn |
| Sep 30, 2018 | 2.61 Mn |
| Jun 30, 2018 | 3.48 Mn |
| Mar 31, 2018 | 2.95 Mn |
| Dec 31, 2017 | 2.94 Mn |
| Sep 30, 2017 | 940,099.00 |
| Jun 30, 2017 | 502,155.00 |
| Mar 31, 2017 | 650,737.00 |
| Dec 31, 2016 | 59,004.00 |
| Sep 30, 2016 | 1.24 Mn |
| Jun 30, 2016 | 836,196.00 |
| Mar 31, 2016 | 617,698.00 |
| Dec 31, 2015 | 393,857.00 |
| Sep 30, 2015 | 648,644.00 |
| Jun 30, 2015 | 534,851.00 |
| Mar 31, 2015 | 777,079.00 |
| Dec 31, 2014 | 916,249.00 |
| Sep 30, 2014 | 587,821.00 |
| Jun 30, 2014 | 881,714.00 |
| Mar 31, 2014 | 719,019.00 |
| Dec 31, 2013 | 171,814.00 |